within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04B_Urologicals.G04BE08_Tadalafil;

model Tadalafil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 6.666666666666666e-07,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.063,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.005833333333333333,
    Tlag = 2160,
    Vdp = 0.208,
    k12 = 8.888888888888888e-06,
    k21 = 8.888888888888888e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Tadalafil</td></tr><tr><td>ATC code:</td><td>G04BE08</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>63</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2.4</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor used for the treatment of erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. It is an orally administered drug, approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult males after a single oral dose administration.</p><h4>References</h4><ol><li><p>Trocóniz, IF, et al., &amp; Forgue, ST (2007). Tadalafil population pharmacokinetics in patients with erectile dysfunction. <i>European journal of clinical pharmacology</i> 63(6) 583–590. DOI:<a href=\"https://doi.org/10.1007/s00228-007-0297-1\">10.1007/s00228-007-0297-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17431603/\">https://pubmed.ncbi.nlm.nih.gov/17431603</a></p></li><li><p>Briganti, A, et al., &amp; Montorsi, F (2005). Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>Nature clinical practice. Urology</i> 2(5) 239–247. DOI:<a href=\"https://doi.org/10.1038/ncpuro0186\">10.1038/ncpuro0186</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16474835/\">https://pubmed.ncbi.nlm.nih.gov/16474835</a></p></li><li><p>Porst, H, et al., &amp; Sharlip, I (2013). SOP conservative (medical and mechanical) treatment of erectile dysfunction. <i>The journal of sexual medicine</i> 10(1) 130–171. DOI:<a href=\"https://doi.org/10.1111/jsm.12023\">10.1111/jsm.12023</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23343170/\">https://pubmed.ncbi.nlm.nih.gov/23343170</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G04BE08 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Tadalafil;
